Literature DB >> 28987705

Evaluation of inter-observer variability according to RECIST 1.1 and its influence on response classification in CT measurement of liver metastases.

Massimo Bellomi1, Francesca De Piano2, Eleonora Ancona3, Alessandra Ferla Lodigiani4, Giuseppe Curigliano5, Sara Raimondi6, Lorenzo Preda7.   

Abstract

OBJECTIVE: The aim of this study is the evaluation of inter-observer variability in the measurement of liver metastases according to RECIST and its influence on response classification. PATIENTS AND METHODS: A total of 100 radiologists measured liver target lesions, on pre- and post-chemotherapy CT scans of three patients. Each observer filled out a questionnaire about his personal and work features. The evaluations of a well experienced radiologist, considered as "the gold standard", were compared to those taken by the observers. The percentage of the observers in agreement with the reviewer, in terms of the response category and in terms of inter-observer variability, was calculated for each patient.
RESULTS: The percentage of the inter-observer agreement was elevated. Most of the observers in agreement with the reviewer were senior radiologists, while those who disagreed were junior radiologist, but this result did not reach a statistical significance. More than 30% of observers disagreed with the reviewer at least in one of the three cases.
CONCLUSIONS: RECIST measurements are reproducible on a large and heterogeneous population of radiologists. Age and expertise of the radiologist remain the most critical factors: this suggests a revision by well-experienced radiologists in clinical trials.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Computed tomography; Inter-observer variability; Oncology; RECIST 1.1

Mesh:

Year:  2017        PMID: 28987705     DOI: 10.1016/j.ejrad.2017.08.001

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  4 in total

1.  Intra- and inter-reader agreement of iRECIST and RECIST 1.1 criteria for the assessment of tumor response in patients receiving checkpoint inhibitor immunotherapy for lung cancer.

Authors:  Sandra Huicochea Castellanos; Andrew Pagano; Andrew J Plodkowski; Jeffrey Girshman; Matthew D Hellmann; Hira Rizvi; Jessica Flynn; Junting Zheng; Marinela Capanu; Darragh F Halpenny; Michelle S Ginsberg
Journal:  Lung Cancer       Date:  2021-09-04       Impact factor: 5.705

2.  Unlocking the Power of Artificial Intelligence and Big Data in Medicine.

Authors:  Christian Lovis
Journal:  J Med Internet Res       Date:  2019-11-08       Impact factor: 5.428

3.  The Value of CT 3D Reconstruction in the Classification and Nursing Effect Evaluation of Ankle Fracture.

Authors:  Pan Xue; Xue Chen; Si Chen; Yuanyuan Shi
Journal:  J Healthc Eng       Date:  2021-08-09       Impact factor: 2.682

4.  Twenty Years On: RECIST as a Biomarker of Response in Solid Tumours an EORTC Imaging Group - ESOI Joint Paper.

Authors:  Laure Fournier; Lioe-Fee de Geus-Oei; Daniele Regge; Daniela-Elena Oprea-Lager; Melvin D'Anastasi; Luc Bidaut; Tobias Bäuerle; Egesta Lopci; Giovanni Cappello; Frederic Lecouvet; Marius Mayerhoefer; Wolfgang G Kunz; Joost J C Verhoeff; Damiano Caruso; Marion Smits; Ralf-Thorsten Hoffmann; Sofia Gourtsoyianni; Regina Beets-Tan; Emanuele Neri; Nandita M deSouza; Christophe M Deroose; Caroline Caramella
Journal:  Front Oncol       Date:  2022-01-10       Impact factor: 6.244

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.